The statin class of HMG-CoA reductase inhibitors demonstrate differential activation of the nuclear receptors PXR, CAR and FXR, as well as their downstream target genes

Xenobiotica

Volumn 41, Issue 7, 2011, Pages 519-529

  Howe, Katharine ^a   Sanat, Faizah ^a   Thumser, Alfred E ^a   Coleman, Tanya ^b   Plant, Nick ^a  

^a UNIVERSITY OF SURREY   (United Kingdom)

^b ASTRAZENECA   (United Kingdom)

Author keywords

constitutive androstane receptor; CYP3A4; drug metabolism; farnesoid X receptor; Gene expression; pregnane X receptor

Indexed keywords

ALKALINE PHOSPHATASE; ATORVASTATIN; CELL NUCLEUS RECEPTOR; COMPLEMENTARY DNA; CONSTITUTIVE ANDROSTANE RECEPTOR; CYTOCHROME P450 3A4; FARNESOID X RECEPTOR; FLUINDOSTATIN; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; MESSENGER RNA; MEVINOLIN; PRAVASTATIN; PREGNANE X RECEPTOR; RIFAMPICIN; ROSUVASTATIN; SIMVASTATIN;

ARTICLE; CONTROLLED STUDY; DOSE RESPONSE; DRUG METABOLISM; DRUG RECEPTOR BINDING; DRUG STRUCTURE; GENE ACTIVATION; GENE CONSTRUCT; GENE EXPRESSION; GENETIC TRANSFECTION; HUMAN; HUMAN CELL; LIGAND BINDING; MOLECULAR DOCKING; MOLECULAR INTERACTION; PROTEIN EXPRESSION; PROTEIN FUNCTION; REGULATORY MECHANISM; REPORTER GENE; TRANSCRIPTION INITIATION;

CELL LINE, TUMOR; CYTOCHROME P-450 CYP3A; DOSE-RESPONSE RELATIONSHIP, DRUG; FLUOROBENZENES; GENE EXPRESSION REGULATION; GENES, REPORTER; HUMANS; HYDROXYMETHYLGLUTARYL-COA REDUCTASE INHIBITORS; ORGANIC ANION TRANSPORTERS; PRAVASTATIN; PYRIMIDINES; RECEPTORS, CYTOPLASMIC AND NUCLEAR; RECEPTORS, STEROID; SULFONAMIDES;

EID: 79958820071     PISSN: 00498254     EISSN: 13665928     Source Type: Journal    
DOI: 10.3109/00498254.2011.569773     Document Type: Article

References (38)

1. Aouabdi S, Gibson G, Plant N. (2006). Transcriptional regulation of the PXR gene: identification and characterization of a functional peroxisome proliferator-activated receptor alpha binding site within the proximal promoter of PXR. Drug Metab Dispos 34:138-144. (Pubitemid 43042655)
2. Billecke S, Draganov D, Counsell R, Stetson P, Watson C, Hsu C, La Du BN. (2000). Human serum paraoxonase (PON1) isozymes Q and R hydrolyze lactones and cyclic carbonate esters. Drug Metab Dispos 28:1335-1342.
3. Bonofiglio D, Gabriele S, Aquila S, Catalano S, Gentile M, Middea E, Giordano F, Andò S. (2005). Estrogen receptor alpha binds to peroxisome proliferator-activated receptor response element and negatively interferes with peroxisome proliferator-activated receptor gamma signaling in breast cancer cells. Clin Cancer Res 11:6139-6147. (Pubitemid 41262940)
4. Bookout AL, Jeong Y, Downes M, Yu RT, Evans RM, Mangelsdorf DJ. (2006). Anatomical profiling of nuclear receptor expression reveals a hierarchical transcriptional network. Cell 126:789-799. (Pubitemid 44233630)
5. Chrencik JE, Orans J, Moore LB, Xue Y, Peng L, Collins JL, Wisely GB, Lambert MH, Kliewer SA, Redinbo MR. (2005). Structural disorder in the complex of human pregnane X receptor and the macrolide antibiotic rifampicin. Mol Endocrinol 19:1125-1134. (Pubitemid 40594113)
6. Dietschy JM, Wilson JD. (1970). Regulation of cholesterol metabolism. N Engl J Med 282:1179-1183.
7. Ding X, Staudinger JL. (2005). The ratio of constitutive androstane receptor to pregnane X receptor determines the activity of guggulsterone against the Cyp2b10 promoter. J Pharmacol Exp Ther 314:120-127. (Pubitemid 41058248)
8. Ekins S, Erickson JA. (2002). A pharmacophore for human pregnane X receptor ligands. Drug Metab Dispos 30:96-99. (Pubitemid 34016946)
9. El-Sankary W, Gibson GG, Ayrton A, Plant N. (2001). Use of a reporter gene assay to predict and rank the potency and efficacy of CYP3A4 inducers. Drug Metab Dispos 29:1499-1504. (Pubitemid 33000699)
10. Everett DW, Chando TJ, Didonato GC, Singhvi SM, Pan HY, Weinstein SH. (1991). Biotransformation of pravastatin sodium in humans. Drug Metab Dispos 19:740-748.
11. Goodwin B, Hodgson E, Liddle C. (1999). The orphan human pregnane X receptor mediates the transcriptional activation of CYP3A4 by rifampicin through a distal enhancer module. Mol Pharmacol 56:1329-1339.
12. Habeos I, Ziros PG, Psyrogiannis A, Vagenakis AG, Papavassiliou AG. (2005). Statins and transcriptional regulation: the FXR connection. Biochem Biophys Res Commun 334:601-605. (Pubitemid 40982409)
13. Handschin C, Meyer UA. (2005). Regulatory network of lipid-sensing nuclear receptors: roles for CAR, PXR, LXR, and FXR. Arch Biochem Biophys 433:387-396. (Pubitemid 39592793)
14. Hirano M, Maeda K, Matsushima S, Nozaki Y, Kusuhara H, Sugiyama Y. (2005). Involvement of BCRP (ABCG2) in the biliary excretion of pitavastatin. Mol Pharmacol 68:800-807. (Pubitemid 41206035)
15. Ho RH, Tirona RG, Leake BF, Glaeser H, Lee W, Lemke CJ, Wang Y, Kim RB. (2006). Drug and bile acid transporters in rosuvastatin hepatic uptake: function, expression, and pharmacogenetics. Gastroenterology 130:1793-1806.
16. Holdgate GA, Ward WH, McTaggart F. (2003). Molecular mechanism for inhibition of 3-hydroxy-3-methylglutaryl CoA (HMG-CoA) reductase by rosuvastatin. Biochem Soc Trans 31:528-531. (Pubitemid 36750725)
17. Ishigami M, Honda T, Takasaki W, Ikeda T, Komai T, Ito K, Sugiyama Y. (2001). A comparison of the effects of 3-hydroxy-3-methylglutaryl-coenzyme a (HMG-CoA) reductase inhibitors on the CYP3A4-dependent oxidation of mexazolam in vitro. Drug Metab Dispos 29:282-288. (Pubitemid 32179528)
18. Kobayashi K, Yamanaka Y, Iwazaki N, Nakajo I, Hosokawa M, Negishi M, Chiba K. (2005). Identification of HMG-CoA reductase inhibitors as activators for human, mouse and rat constitutive androstane receptor. Drug Metab Dispos 33:924-929. (Pubitemid 41002773)
19. Lennernäs H, Fager G. (1997). Pharmacodynamics and pharmacokinetics of the HMG-CoA reductase inhibitors. Similarities and differences. Clin Pharmacokinet 32:403-425. (Pubitemid 27199232)
20. Linsel-Nitschke P, Tall AR. (2005). HDL as a target in the treatment of atherosclerotic cardiovascular disease. Nat Rev Drug Discov 4:193-205. (Pubitemid 40372554)
21. Maglich JM, Parks DJ, Moore LB, Collins JL, Goodwin B, Billin AN, Stoltz CA, Kliewer SA, Lambert MH, Willson TM, Moore JT. (2003). Identification of a novel human constitutive androstane receptor (CAR) agonist and its use in the identification of CAR target genes. J Biol Chem 278:17277-17283. (Pubitemid 36799610)
22. Maglich JM, Stoltz CM, Goodwin B, Hawkins-Brown D, Moore JT, Kliewer SA. (2002). Nuclear pregnane x receptor and constitutive androstane receptor regulate overlapping but distinct sets of genes involved in xenobiotic detoxification. Mol Pharmacol 62:638-646. (Pubitemid 36329382)
23. Morris GM, Huey R, Lindstrom W, Sanner MF, Belew RK, Goodsell DS, Olson AJ. (2009). AutoDock4 and AutoDockTools4: automated docking with selective receptor flexibility. J Comput Chem 30:2785-2791.
24. Nakabayashi H, Taketa K, Miyano K, Yamane T, Sato J. (1982). Growth of human hepatoma cells lines with differentiated functions in chemically defined medium. Cancer Res 42:3858-3863. (Pubitemid 12054507)
25. Nakai D, Nakagomi R, Furuta Y, Tokui T, Abe T, Ikeda T, Nishimura K. (2001). Human liver-specific organic anion transporter, LST-1, mediates uptake of pravastatin by human hepatocytes. J Pharmacol Exp Ther 297:861-867. (Pubitemid 32472480)
26. Neuvonen PJ, Niemi M, Backman JT. (2006). Drug interactions with lipid-lowering drugs: mechanisms and clinical relevance. Clin Pharmacol Ther 80:565-581. (Pubitemid 44908269)
27. Olsson AG, Pears J, McKellar J, Mizan J, Raza A. (2001). Effect of rosuvastatin on low-density lipoprotein cholesterol in patients with hypercholesterolemia. Am J Cardiol 88:504-508. (Pubitemid 32778495)
28. Pascussi JM, Busson-Le Coniat M, Maurel P, Vilarem MJ. (2003). Transcriptional analysis of the orphan nuclear receptor constitutive androstane receptor (NR1I3) gene promoter: identification of a distal glucocorticoid response element. Mol Endocrinol 17:42-55. (Pubitemid 36132658)
29. Plant N. (2004). Interaction networks: coordinating responses to xenobiotic exposure. Toxicology 202:21-32.
30. Plant N. (2007). The human cytochrome P450 sub-family: transcriptional regulation, inter-individual variation and interaction networks. Biochim Biophys Acta 1770:478-488.
31. Plant N, Aouabdi S. (2009). Nuclear receptors: the controlling force in drug metabolism of the liver? Xenobiotica 39:597-605.
32. Raucy J, Warfe L, Yueh MF, Allen SW. (2002). A cell-based reporter gene assay for determining induction of CYP3A4 in a high-volume system. J Pharmacol Exp Ther 303:412-423.
33. Rizzo G, Renga B, Mencarelli A, Pellicciari R, Fiorucci S. (2005). Role of FXR in regulating bile acid homeostasis and relevance for human diseases. Curr Drug Targets Immune Endocr Metabol Disord 5:289-303. (Pubitemid 41131707)
34. Sirvent P, Mercier J, Lacampagne A. (2008). New insights into mechanisms of statin-associated myotoxicity. Curr Opin Pharmacol 8:333-338.
35. Vaklavas C, Chatzizisis YS, Ziakas A, Zamboulis C, Giannoglou GD. (2009). Molecular basis of statin-associated myopathy. Atherosclerosis 202:18-28.
36. Wagner M, Halilbasic E, Marschall HU, Zollner G, Fickert P, Langner C, Zatloukal K, Denk H, Trauner M. (2005). CAR and PXR agonists stimulate hepatic bile acid and bilirubin detoxification and elimination pathways in mice. Hepatology 42:420-430. (Pubitemid 41061095)
37. Watanabe H, Kosuge K, Nishio S, Yamada H, Uchida S, Satoh H, Hayashi H, Ishizaki T, Ohashi K. (2004). Pharmacokinetic and pharmacodynamic interactions between simvastatin and diltiazem in patients with hypercholesterolemia and hypertension. Life Sci 76:281-292. (Pubitemid 39456434)
38. Yamasaki D, Nakamura T, Okamura N, Kokudai M, Inui N, Takeuchi K, Watanabe H, Hirai M, Okumura K, Sakaeda T. (2009). Effects of acid and lactone forms of 3-hydroxy-3-methylglutaryl coenzyme A reductase inhibitors on the induction of MDR1 expression and function in LS180 cells. Eur J Pharm Sci 37:126-132.